Press

Special focus issue on innovation in pain management: BVMed, Earlybird and High-Tech Gründerfonds publish „MedTech Radar 4“

Innovation resulting from research in the field of pain and the clinical management of pain are the topic of Med-Tech-Radars’ fourth issue. MedTech Radar is a joint publication of BVMed (The German Medical Technology Association), Earlybird Venture Capital and High-Tech Gründerfonds. 12-15 million people in Germany alone suffer from chronic and recurring pain. Chosing the right therapy and getting the dosage right still proves a demanding task for medical professionals. Berlin-based Dolosys now sets out to establish an innovative method allowing for the objective quantification of pain. This issue will further focus on the overall innovation climate in the medtech field in Germany. The current issue of MedTechRadar is available in both German and English. 

Persistent and chronic pain often severly reduces quality of life of affected patients adding to the need of individually adjusted therapy and patient-specific drug dosage. Currently, medical professionals often find this challenging and while modern medical technology offers a range of different methods and approaches to reduce the patient’s sensation of pain they do not assist the medical staff at finding the right dosage of the drugs they use. Dosage-related decisions become especially tough when treating sedated or otherwise non-aware patients.

The present fourth editions of MedTech-Radar showcases Berlin-based Dolosys GmbH and covers the company’s efforts in developing and producing a medical device for the objective and individuall mesaurement of pain and analgesia. “With the pain tracker doctors will have a tool at hand that gives them an objective and specific indication on the current state of analgesia”, comments Dolosys’ managing director, PD Dr. med. Jan Baars on Dolosys’ pain monitoring device.

“Our MedTech Radar is meant to provide continous insights into the developments of the innovative space of medtech products”, says BVMed’s managing director and member of the board, Joachim M. Schmitt. “ We would like to highlight the existential role that innovation financing plays when it comes to translating science into patient benedefits”, adds Dr. Michael Brandkamp, Managing Director of High-Tech Gründerfonds. “Based on case studies, we want to illustrate the complex path a medical product has to take from bench to bedside”, says Thom Rasche, Partner at Earlybird Venture.

 You can read the complete issue of MedTech Radar 4 here.

About the publishers:
High-Tech Gründerfonds invests venture capital in young, high-opportunity companies that turn promising research results into business.

Earlybird Venture Capital is one of the most successful European venture investors and currently manages over €700 million in capital for an international investor base.

The German Medical Technology Association (BVMed) is a trade association representing over 230 industrial and commercial companies in the medical technology sector.

Responsible for content under German press law:
The German Medical Technology Association (BVMed), Reinhardtstr. 29 b, 10117 Berlin
Manfred Beeres, Head of Communication/Press; tel. +49 – 30 246 255-20, beeres@bvmed.de , www.bvmed.de  

Earlybird Venture Capital GmbH & Co KG, Maximilianstr. 14, 80539 München
Catrin Schmidt; Tel. +49 – 30 46724700, schmidt@earlybird.com , www.earlybird.com  

High-Tech Gründerfonds Management GmbH, Schlegelstraße 2, 53113 Bonn
Stefanie Zillikens; Tel. +49 – 228 82300107, s.zillikens@htgf.de , www.htgf.de

Kommentare

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments